Thomas John Dietz

Insider · Director · CYPH

Thomas John Dietz files insider transactions with the SEC as a director of Cypherpunk Technologies (CYPH). We hold 1 disclosed purchase or sale filed since 11 April 2013, 1 of them in the last 90 days.

Files forCYPH
Disclosed buys and sells1 in all, 1 in the last 90 days
Last disclosure27 August 2026

Positions held

5 posts we hold — a term names its own dates; a run of filings only says when they filed

Filed 11 November 2025 — 26 August 2026Director · Cypherpunk Technologies (CYPH)11 Form 4 lines · source: SEC Form 4
Filed 23 January 2017 — 2 October 2024Director · Leap Therapeutics (LPTX)15 Form 4 lines · source: SEC Form 4
Filed 4 February 2015 — 21 September 2023Director · Paratek Pharmaceuticals (PRTK)26 Form 4 lines · source: SEC Form 4
Filed 28 March 2016 — 1 March 2023Director · Eiger BioPharmaceuticals (EIGR)24 Form 4 lines · source: SEC Form 4
Filed 10 April 2013 — 30 October 2014Director · Transcept Pharmaceuticals (TSPT)4 Form 4 lines · source: SEC Form 4

Everything they disclosed

80 entries, newest first — one per disclosure report, one per Form 4 line

▼ sold on the open market 20,000 shares of Cypherpunk TechnologiesSEC Form 427 August 2026Common Stock · traded 26 August 2026 · filed 27 August 2026
was granted 100,000 shares of Cypherpunk Technologies (a derivative holding)SEC Form 42 July 2026Restricted Stock Units · traded 1 July 2026 · filed 2 July 2026
exercised options over 104,500 shares of Cypherpunk TechnologiesSEC Form 417 March 2026Common Stock · traded 13 March 2026 · filed 17 March 2026
exercised options over 104,500 shares of Cypherpunk Technologies (a derivative holding)SEC Form 417 March 2026Restricted Stock Units · traded 13 March 2026 · filed 17 March 2026
exercised options over 104,500 shares of Cypherpunk Technologies (a derivative holding)SEC Form 417 March 2026Restricted Stock Units · traded 13 March 2026 · filed 17 March 2026
exercised options over 104,500 shares of Cypherpunk TechnologiesSEC Form 417 March 2026Common Stock · traded 13 March 2026 · filed 17 March 2026
exercised options over 83,000 shares of Cypherpunk Technologies (a derivative holding)SEC Form 430 December 2025Restricted Stock Units · traded 26 December 2025 · filed 30 December 2025
was granted 104,500 shares of Cypherpunk Technologies (a derivative holding)SEC Form 430 December 2025Restricted Stock Units · traded 23 December 2025 · filed 30 December 2025
exercised options over 83,000 shares of Cypherpunk TechnologiesSEC Form 430 December 2025Common Stock · traded 26 December 2025 · filed 30 December 2025
had shares withheld for tax on 35,000 shares of Cypherpunk TechnologiesSEC Form 430 December 2025Common Stock · traded 26 December 2025 · filed 30 December 2025
was granted 83,000 shares of Cypherpunk Technologies (a derivative holding)SEC Form 413 November 2025Restricted Stock Units · traded 11 November 2025 · filed 13 November 2025
was granted 30,000 shares of Leap Therapeutics (a derivative holding)SEC Form 44 October 2024Stock Option (Right to Buy) · traded 2 October 2024 · filed 4 October 2024
was granted 30,000 shares of Leap Therapeutics (a derivative holding)SEC Form 431 January 2024Stock Option (Right to Buy) · traded 29 January 2024 · filed 31 January 2024
returned to the issuer 7,000 shares of Paratek Pharmaceuticals (a derivative holding)SEC Form 421 September 2023Stock option (right to buy) · traded 21 September 2023 · filed 21 September 2023
returned to the issuer 7,000 shares of Paratek Pharmaceuticals (a derivative holding)SEC Form 421 September 2023Stock option (right to buy) · traded 21 September 2023 · filed 21 September 2023
returned to the issuer 5,000 shares of Paratek Pharmaceuticals (a derivative holding)SEC Form 421 September 2023Stock option (right to buy) · traded 21 September 2023 · filed 21 September 2023
returned to the issuer 5,000 shares of Paratek Pharmaceuticals (a derivative holding)SEC Form 421 September 2023Stock option (right to buy) · traded 21 September 2023 · filed 21 September 2023
returned to the issuer 6,000 shares of Paratek Pharmaceuticals (a derivative holding)SEC Form 421 September 2023Stock option (right to buy) · traded 21 September 2023 · filed 21 September 2023
returned to the issuer 12,000 shares of Paratek Pharmaceuticals (a derivative holding)SEC Form 421 September 2023Stock option (right to buy) · traded 21 September 2023 · filed 21 September 2023
returned to the issuer 20,000 shares of Paratek Pharmaceuticals (a derivative holding)SEC Form 421 September 2023Stock option (right to buy) · traded 21 September 2023 · filed 21 September 2023
returned to the issuer 49,250 shares of Paratek PharmaceuticalsSEC Form 421 September 2023Common Stock · traded 21 September 2023 · filed 21 September 2023
returned to the issuer 20,000 shares of Paratek PharmaceuticalsSEC Form 421 September 2023Common Stock · traded 21 September 2023 · filed 21 September 2023
was granted 17,500 shares of Leap Therapeutics (a derivative holding)SEC Form 425 August 2023Stock Option (Right to Buy) · traded 23 August 2023 · filed 25 August 2023
was granted 175,000 shares of Leap Therapeutics (a derivative holding)SEC Form 44 April 2023Stock Option (Right to Buy) · traded 31 March 2023 · filed 4 April 2023
was granted 40,000 shares of Eiger BioPharmaceuticals (a derivative holding)SEC Form 43 March 2023Stock Option (Right to Buy) · traded 1 March 2023 · filed 3 March 2023
was granted 20,000 shares of Paratek PharmaceuticalsSEC Form 49 February 2023Common Stock · traded 8 February 2023 · filed 9 February 2023
▲ bought on the open market 50,000 shares of Eiger BioPharmaceuticalsSEC Form 425 January 2023Common Stock · traded 23 January 2023 · filed 25 January 2023
▼ sold on the open market 22,500 shares of Eiger BioPharmaceuticalsSEC Form 427 December 2022Common Stock · traded 22 December 2022 · filed 27 December 2022
was granted 30,000 shares of Leap Therapeutics (a derivative holding)SEC Form 42 September 2022Stock Option (Right to Buy) · traded 1 September 2022 · filed 2 September 2022
was granted 24,000 shares of Eiger BioPharmaceuticals (a derivative holding)SEC Form 411 March 2022Stock Option (Right to Buy) · traded 11 March 2022 · filed 11 March 2022
was granted 6,000 shares of Eiger BioPharmaceuticalsSEC Form 411 March 2022Common Stock · traded 11 March 2022 · filed 11 March 2022
was granted 20,000 shares of Paratek PharmaceuticalsSEC Form 418 February 2022Common Stock · traded 16 February 2022 · filed 18 February 2022
was granted 60,000 shares of Leap Therapeutics (a derivative holding)SEC Form 42 February 2022Stock Option (Right to Buy) · traded 31 January 2022 · filed 2 February 2022
▲ bought on the open market 1,500 shares of Eiger BioPharmaceuticalsSEC Form 412 April 2021Common Stock · traded 9 April 2021 · filed 12 April 2021
▲ bought on the open market 1,000 shares of Eiger BioPharmaceuticalsSEC Form 412 April 2021Common Stock · traded 9 April 2021 · filed 12 April 2021
was granted 5,000 shares of Eiger BioPharmaceuticalsSEC Form 415 March 2021Common Stock · traded 12 March 2021 · filed 15 March 2021
was granted 20,000 shares of Eiger BioPharmaceuticals (a derivative holding)SEC Form 415 March 2021Stock Option (Right to Buy) · traded 12 March 2021 · filed 15 March 2021
was granted 9,000 shares of Paratek PharmaceuticalsSEC Form 422 February 2021Common Stock · traded 18 February 2021 · filed 22 February 2021
was granted 7,000 shares of Paratek Pharmaceuticals (a derivative holding)SEC Form 422 February 2021Stock Option (right to buy) · traded 18 February 2021 · filed 22 February 2021
was granted 37,300 shares of Leap Therapeutics (a derivative holding)SEC Form 46 January 2021Stock Option (Right to Buy) · traded 4 January 2021 · filed 6 January 2021
was granted 12,500 shares of Leap Therapeutics (a derivative holding)SEC Form 412 August 2020Stock Option (Right to Buy) · traded 10 August 2020 · filed 12 August 2020
was granted 12,500 shares of Leap Therapeutics (a derivative holding)SEC Form 413 April 2020Stock Option (Right to Buy) · traded 9 April 2020 · filed 13 April 2020
▲ bought on the open market 1,000 shares of Eiger BioPharmaceuticalsSEC Form 417 March 2020Common Stock · traded 16 March 2020 · filed 17 March 2020
was granted 20,000 shares of Eiger BioPharmaceuticals (a derivative holding)SEC Form 413 March 2020Stock Option (Right to Buy) · traded 12 March 2020 · filed 13 March 2020
was granted 5,000 shares of Eiger BioPharmaceuticalsSEC Form 413 March 2020Common Stock · traded 12 March 2020 · filed 13 March 2020
was granted 25,000 shares of Leap Therapeutics (a derivative holding)SEC Form 44 March 2020Stock Option (Right to Buy) · traded 2 March 2020 · filed 4 March 2020
was granted 7,000 shares of Paratek Pharmaceuticals (a derivative holding)SEC Form 421 February 2020Stock Option (right to buy) · traded 19 February 2020 · filed 21 February 2020
was granted 9,000 shares of Paratek PharmaceuticalsSEC Form 421 February 2020Common Stock · traded 19 February 2020 · filed 21 February 2020
▲ bought on the open market 4,000 shares of Eiger BioPharmaceuticalsSEC Form 413 January 2020Common Stock · traded 10 January 2020 · filed 13 January 2020
was granted 15,000 shares of Leap Therapeutics (a derivative holding)SEC Form 412 June 2019Stock Option (Right to Buy) · traded 11 June 2019 · filed 12 June 2019
▲ bought on the open market 5,000 shares of Eiger BioPharmaceuticalsSEC Form 423 April 2019Common Stock · traded 23 April 2019 · filed 23 April 2019
▲ bought on the open market 5,000 shares of Eiger BioPharmaceuticalsSEC Form 422 April 2019Common Stock · traded 22 April 2019 · filed 22 April 2019
was granted 20,000 shares of Eiger BioPharmaceuticals (a derivative holding)SEC Form 425 March 2019Stock Option ( Right to Buy) · traded 21 March 2019 · filed 25 March 2019
was granted 5,000 shares of Paratek Pharmaceuticals (a derivative holding)SEC Form 428 February 2019Stock Option (right to buy) · traded 26 February 2019 · filed 28 February 2019
was granted 7,500 shares of Paratek PharmaceuticalsSEC Form 428 February 2019Common Stock · traded 26 February 2019 · filed 28 February 2019
▼ sold on the open market 3,000 shares of Paratek PharmaceuticalsSEC Form 420 February 2019Common Stock · traded 15 February 2019 · filed 20 February 2019
was granted 9,375 shares of Leap Therapeutics (a derivative holding)SEC Form 43 January 2019Stock Option (Right to Buy) · traded 1 January 2019 · filed 3 January 2019
▼ sold on the open market 9,330 shares of Paratek PharmaceuticalsSEC Form 426 December 2018Common Stock · traded 21 December 2018 · filed 26 December 2018
▲ bought on the open market 5,000 shares of Eiger BioPharmaceuticalsSEC Form 420 December 2018Common Stock · traded 20 December 2018 · filed 20 December 2018
▲ bought on the open market 5,000 shares of Eiger BioPharmaceuticalsSEC Form 410 December 2018Common Stock · traded 6 December 2018 · filed 10 December 2018
was granted 11,250 shares of Leap Therapeutics (a derivative holding)SEC Form 420 April 2018Stock Option (Right to Buy) · traded 18 April 2018 · filed 20 April 2018
was granted 10,000 shares of Eiger BioPharmaceuticals (a derivative holding)SEC Form 416 March 2018Stock Option (Right to Buy) · traded 14 March 2018 · filed 16 March 2018
was granted 5,000 shares of Paratek Pharmaceuticals (a derivative holding)SEC Form 416 February 2018Stock Option (right to buy) · traded 14 February 2018 · filed 16 February 2018
was granted 7,500 shares of Paratek PharmaceuticalsSEC Form 416 February 2018Common Stock · traded 14 February 2018 · filed 16 February 2018
▼ sold on the open market 2,100 shares of Paratek PharmaceuticalsSEC Form 47 February 2018Common Stock · traded 5 February 2018 · filed 7 February 2018
was granted 10,000 shares of Eiger BioPharmaceuticals (a derivative holding)SEC Form 413 April 2017Stock Option (Right to Buy) · traded 12 April 2017 · filed 13 April 2017
was granted 6,000 shares of Paratek PharmaceuticalsSEC Form 46 February 2017Common Stock · traded 2 February 2017 · filed 6 February 2017
was granted 6,000 shares of Paratek Pharmaceuticals (a derivative holding)SEC Form 46 February 2017Stock Option (right to buy) · traded 2 February 2017 · filed 6 February 2017
was granted 11,000 shares of Leap Therapeutics (a derivative holding)SEC Form 423 January 2017Stock Option (Right to Buy) · traded 23 January 2017 · filed 23 January 2017
was granted 15,000 shares of Leap Therapeutics (a derivative holding)SEC Form 423 January 2017Stock Option (Right to Buy) · traded 23 January 2017 · filed 23 January 2017
was granted 25,000 shares of Eiger BioPharmaceuticals (a derivative holding)SEC Form 415 September 2016Stock Option (Right to Buy) · traded 28 March 2016 · filed 15 September 2016
was granted 23,000 shares of Eiger BioPharmaceuticals (a derivative holding)SEC Form 415 September 2016Stock Option (Right to Buy) · traded 28 March 2016 · filed 15 September 2016
was granted 25,000 shares of Eiger BioPharmaceuticals (a derivative holding)SEC Form 41 April 2016Stock Option (Right to Buy) · traded 28 March 2016 · filed 1 April 2016
was granted 23,000 shares of Eiger BioPharmaceuticals (a derivative holding)SEC Form 41 April 2016Stock Option (Right to Buy) · traded 28 March 2016 · filed 1 April 2016
was granted 12,000 shares of Paratek Pharmaceuticals (a derivative holding)SEC Form 48 February 2016Stock Option (right to buy) · traded 4 February 2016 · filed 8 February 2016
was granted 20,000 shares of Paratek Pharmaceuticals (a derivative holding)SEC Form 46 February 2015Stock Option (right to buy) · traded 4 February 2015 · filed 6 February 2015
was granted 5,430 shares of Transcept PharmaceuticalsSEC Form 430 October 2014Common Stock · traded 30 October 2014 · filed 30 October 2014
returned to the issuer 2,083 shares of Transcept Pharmaceuticals (a derivative holding)SEC Form 430 October 2014Stock option (right to buy) · traded 30 October 2014 · filed 30 October 2014
returned to the issuer 1,666 shares of Transcept Pharmaceuticals (a derivative holding)SEC Form 430 October 2014Stock option (right to buy) · traded 30 October 2014 · filed 30 October 2014
was granted 25,000 shares of Transcept Pharmaceuticals (a derivative holding)SEC Form 411 April 2013Common Stock Option (right to buy) · traded 10 April 2013 · filed 11 April 2013

Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.